Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Biological: Bordetella pertussis J820

Phase 1Biologic

DDalhousie University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Infection

NCT06827470

Clinical

Trials by Indication[1]

Infection1 trial

Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella Pertussis

Recruiting·—·Phase 1·NCT06827470·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Biological: Bordetella pertussis J820. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biological: Bordetella pertussis J820 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biological: Bordetella pertussis J820. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dalhousie University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: DDalhousie University

Related News